Insider Transactions in Q1 2021 at Turning Point Therapeutics, Inc. (TPTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2021
|
Brian Lee Baker SVP of Finance and Admin. |
SELL
Open market or private sale
|
Direct |
28,435
-23.39%
|
$2,843,500
$100.99 P/Share
|
|
Mar 23
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
28,435
+22.88%
|
$113,740
$4.49 P/Share
|
|
Mar 22
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
1,625
+28.31%
|
-
|
|
Mar 08
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
20,000
-22.7%
|
$2,160,000
$108.95 P/Share
|
|
Mar 08
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+43.03%
|
$340,000
$17.0 P/Share
|
|
Mar 04
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
35,550
-19.9%
|
$3,768,300
$106.52 P/Share
|
|
Mar 04
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,550
+47.43%
|
$1,813,050
$51.28 P/Share
|
|
Feb 11
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
8,942
-5.3%
|
$1,225,054
$137.55 P/Share
|
|
Feb 11
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,942
+13.13%
|
$26,826
$3.2 P/Share
|
|
Feb 10
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
25,392
-7.43%
|
$3,453,312
$136.43 P/Share
|
|
Feb 10
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,392
+25.15%
|
$76,176
$3.2 P/Share
|
|
Feb 09
2021
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
25,666
-7.64%
|
$3,541,908
$138.49 P/Share
|
|
Feb 09
2021
|
Athena Countouriotis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,666
+15.03%
|
$76,998
$3.2 P/Share
|
|
Feb 08
2021
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
22,617
+31.06%
|
-
|
|
Feb 08
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
1,483
+37.32%
|
-
|
|
Feb 08
2021
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,845
+50.0%
|
-
|
|
Feb 08
2021
|
Yi Larson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,617
+38.67%
|
-
|
|
Feb 08
2021
|
Andrew John Partridge EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,136
+8.29%
|
-
|
|
Feb 08
2021
|
Annette North EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,483
+50.0%
|
-
|
|
Feb 08
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,483
+48.93%
|
-
|
|
Feb 02
2021
|
Yi Larson EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,298
-26.34%
|
$1,844,442
$129.62 P/Share
|
|
Feb 02
2021
|
Yi Larson EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,298
+45.68%
|
$772,092
$54.03 P/Share
|
|
Feb 02
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
9,016
-41.19%
|
$1,163,064
$129.25 P/Share
|
|
Feb 02
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
9,016
+50.0%
|
$153,272
$17.0 P/Share
|
|
Feb 01
2021
|
Yi Larson EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,702
-34.57%
|
$1,947,048
$124.33 P/Share
|
|
Feb 01
2021
|
Yi Larson EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,702
+46.04%
|
$847,908
$54.03 P/Share
|
|
Feb 01
2021
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
15,984
-67.63%
|
$1,966,032
$123.97 P/Share
|
|
Feb 01
2021
|
Annette North EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
15,984
+50.0%
|
$271,728
$17.0 P/Share
|
|
Jan 07
2021
|
Brian Lee Baker SVP of Finance and Admin. |
SELL
Open market or private sale
|
Direct |
31,238
-31.43%
|
$3,779,798
$121.97 P/Share
|
|
Jan 07
2021
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
28,438
+23.13%
|
$113,752
$4.49 P/Share
|
|
Jan 05
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,253
-81.52%
|
$150,360
$120.0 P/Share
|
|
Jan 05
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,253
+44.91%
|
$67,662
$54.73 P/Share
|
|
Jan 04
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,047
-50.04%
|
$1,094,687
$121.43 P/Share
|
|
Jan 04
2021
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,747
+48.38%
|
$472,338
$54.73 P/Share
|